Two former executives from Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allege | ...
The global, double-blinded phase 3 study enrolled 165 patients aged between 12 and 75 years and measured the time to onset ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...
That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
Abbott is teaming up with AtaCor Medical to develop a next-generation implantable cardioverter defibrillator (ICD) designed ...
Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...
Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback